331 related articles for article (PubMed ID: 23327964)
41. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma.
Bansal M; Gandhi M; Ferris RL; Nikiforova MN; Yip L; Carty SE; Nikiforov YE
Am J Surg Pathol; 2013 Oct; 37(10):1586-91. PubMed ID: 23797723
[TBL] [Abstract][Full Text] [Related]
42. [Invasive properties of papillary thyroid cancer with concurrent BRAF(V600E) mutation and rearranged during transfection proto-oncogene protein expression].
Meng C; Gao J; Liang J; Liang ZY; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):64-8. PubMed ID: 23469793
[TBL] [Abstract][Full Text] [Related]
43. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus.
Smida J; Salassidis K; Hieber L; Zitzelsberger H; Kellerer AM; Demidchik EP; Negele T; Spelsberg F; Lengfelder E; Werner M; Bauchinger M
Int J Cancer; 1999 Jan; 80(1):32-8. PubMed ID: 9935226
[TBL] [Abstract][Full Text] [Related]
44. BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia.
Zhou D; Li Z; Bai X
Med Sci Monit; 2018 Sep; 24():6795-6808. PubMed ID: 30254191
[TBL] [Abstract][Full Text] [Related]
45. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
[TBL] [Abstract][Full Text] [Related]
46. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Salvatore G; Giannini R; Faviana P; Caleo A; Migliaccio I; Fagin JA; Nikiforov YE; Troncone G; Palombini L; Basolo F; Santoro M
J Clin Endocrinol Metab; 2004 Oct; 89(10):5175-80. PubMed ID: 15472223
[TBL] [Abstract][Full Text] [Related]
47. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC
Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496
[TBL] [Abstract][Full Text] [Related]
48. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
49. [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
Zhu XL; Zhou XY; Zhang TM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):87-91. PubMed ID: 16630482
[TBL] [Abstract][Full Text] [Related]
50. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
51. Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyroid carcinoma.
Brahma B; Yulian ED; Ramli M; Setianingsih I; Gautama W; Brahma P; Sastroasmoro S; Harimurti K
Asian Pac J Cancer Prev; 2013; 14(1):31-7. PubMed ID: 23534744
[TBL] [Abstract][Full Text] [Related]
52.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
53. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.
Henderson YC; Ahn SH; Clayman GL
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):347-54. PubMed ID: 19380355
[TBL] [Abstract][Full Text] [Related]
54. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
55. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
56. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
57. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant.
Thomas GA; Bunnell H; Cook HA; Williams ED; Nerovnya A; Cherstvoy ED; Tronko ND; Bogdanova TI; Chiappetta G; Viglietto G; Pentimalli F; Salvatore G; Fusco A; Santoro M; Vecchio G
J Clin Endocrinol Metab; 1999 Nov; 84(11):4232-8. PubMed ID: 10566678
[TBL] [Abstract][Full Text] [Related]
58. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
[TBL] [Abstract][Full Text] [Related]
59. Radiation induced thyroid cancer: fundamental and applied aspects.
Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
[TBL] [Abstract][Full Text] [Related]
60. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima.
Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
